Moderate ResearchHealing & RecoveryLongevity

Vesugen

KED

KED | Vascular Bioregulator Peptide

Half-life

Not established

Chain length

3 amino acids

Reference frequency

Daily for 10-20 consecutive days (Khavinson bioregulator cycle)

Research overview

DoseGear research brief

Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression.

Mechanism of action

Vesugen works through epigenetic regulation by interacting with DNA promoter regions, particularly affecting Ki-67 gene expression which controls cell division. It plays a prominent role in regulating sirtuin 1 (SIRT1) protein levels - a key anti-aging protein activated during calorie restriction. Vesugen enhances mesenchymal stem cell proliferation, reduces senescence markers, improves cell differentiation, and may reverse the Senescence-Associated Secretory Phenotype (SASP) implicated in age-related cardiovascular disease.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Khavinson-associated vascular bioregulator peptide.

What it is researched for

Experimental endothelial and vascular regulation through proposed endothelial gene-expression and cellular effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Chart reference	500 mcg	Daily · See source guide	Injectable · 20 mg lyophilized vial + 3 mL BAC Water

Reference cycle

10-20 day cycle

Reference storage

Lyophilized powder/reconstituted: 2-8°C refrigerated

Safety context

Reported side effects

Generally well-tolerated
Minimal side effects reported

Contraindications & cautions

Active cardiovascular emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding

Scientific references

01
Khavinson Peptide Bioregulators Research
Scientific citationKhavinson Peptide Bioregulators Research. Advances in Gerontology (2020).
02
Short Peptides and Vascular Aging
Scientific citationShort Peptides and Vascular Aging. Bulletin of Experimental Biology and Medicine (2018).
03
Mesenchymal Stem Cell Activation by Peptide Bioregulators
Scientific citationMesenchymal Stem Cell Activation by Peptide Bioregulators. Cell Technologies in Biology and Medicine (2019).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity